Semaglutide.
Wegovy · Ozempic · Rybelsus · compounded
GLP-1 mono-agonist made by Novo Nordisk. The longest real-world safety record of the GLP-1 class, the broadest brand availability (including an oral form), and tighter global supply through 2025 to 2026 than tirzepatide in most markets.
NHS (T2D only). Prescription charge if NHS covers for T2D. Wegovy NHS pathway exists but with strict referral criteria; most patients fall outside it.
See all regions ranked →Mechanism + ceiling
Selective GLP-1 receptor agonist. Slows gastric emptying, increases satiety, improves glucose-dependent insulin secretion. The same mechanism powers the diabetes brand (Ozempic), the weight-management brand (Wegovy), and the oral form (Rybelsus, lower bioavailability and higher dose).
STEP-1 reported 14.9% mean body-weight reduction at 2.4 mg over 68 weeks. Lower than tirzepatide head-to-head, but the safety dataset is much deeper (Ozempic has been on market since 2017).
Approved for type-2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy) in nearly every regulated market. Supply has been the dominant constraint in the UK, Europe, and parts of Asia through 2025; allocation is improving in 2026 but Wegovy remains harder to fill than Ozempic in most apoteks.
13 regions, sorted cheapest first
Each region links to its full breakdown — pricing bands, vendor channels, legal routes, supply state, practical notes for travelers and residents.
Where to next
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.